delpazolid + vancomycin

Delpazolid + vancomycin is a combination therapy of delpazolid, an investigational oxazolidinone-class antibiotic, and vancomycin, a glycopeptide antibiotic, primarily evaluated for the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia. Delpazolid inhibits bacterial protein synthesis by binding to domain V of 23S rRNA of the 50S ribosomal subunit, thereby blocking the initiation step of translation. Vancomycin inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of cell wall precursor units. The combination is being studied due to its potential synergistic antibacterial action and improved efficacy compared to vancomycin monotherapy, particularly for drug-resistant Gram-positive infections[1][3][4][6].

Other names

delpazolid + vancomycin